Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13176911 | 0.82 | MAOA (0.48) | MAOAMAOBALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL6542864 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MAPTL3MBTL1TACR2KDM4E | |
| SCHEMBL3954569 | 0.77 | RXRA (0.52) | MAOAMAOBALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL29446267 | 0.77 | TACR2 (0.62) | MAOAMAOBALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL584489 | 0.77 | TACR2 (0.62) | MAOAMAOBALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2461447 | 0.76 | MAOA (0.56) | MAOAMAOBALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL6542213 | 0.76 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| Trifluoromethanesulfonic Acid SCHEMBL1110880 | 0.76 | MAOA (0.42) | MAOAMAOBALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL3956772 | 0.76 | MAOA (0.52) | MAOAMAOBALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL5217355 | 0.75 | TACR2 (0.54) | MAOAMAOBALDH1A1SMN1; SMN2TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313731-B1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | UCB SA (BE) | 2010-09-29 | — | — | EP | disclosed |
| US-6740670-B2 | SUCH AS 5-(((3-(N-METHYL-N-PHENYLAMINO)CARBONYL-4-(PHENYL-METHOXY)) -PHENYL)METHYLENE)-4-OXO-2-THIOXO-3-THIAZOLIDINE-ACETIC ACID | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2004-05-25 | — | — | US | disclosed |
| US-20030216453-A1 | Thiazolidine derivatives and its use as antifungal agent | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1313731-A1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | Oxford GlycoSciences (UK) Limited (GB) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002022612-A1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216453-A1 | Thiazolidine derivatives and its use as antifungal agent | CYP3A7, TAS2R7, OXSR1 | MAOA 3397/4885MAOB 2540/4885ALDH1A1 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.